Breast Cancer Treatment Market Scope
Breast cancer treatment is growth of abnormal cell in different parts of breast most likely in women’s but breast cancer also found in male also. There are five major type of therapy used to control the growth and treat the breast cancer cells namely chemotherapy, radiation therapy, hormone therapy, immunotherapy, targeted drug therapy. These therapies are used according to type of cancer such as ductal carcinoma in situ (DSIS), invasive ductal carcinoma (IDC), lobular carcinoma in situ (LCIS), invasive lobular cancer (ILC), among others. Breast cancer treatment contain different categories of drugs such as monoclonal antibodies, antibody-drug conjugates, kinase inhibitors, CDK4/6, among others. Growing demand for breast cancer treatments due to rise in breast cancer patients give drive to the breast cancer treatment market
|Unit||Value (USD Million)|
|Key Companies Profiled||F. Hoffman - La Roche Ltd. (Switzerland), Celgene Corporation (United States), Bristol-Myers Squibb Company (United States), Abbot Laboratories Inc. (United States), Johnson & Johnson Services, Inc. (United States), Pfizer, Inc. (United States), AstraZeneca PLC (United Kingdom), Merck & Co. (United States), Novartis AG (Switzerland), AbbVie (United States), Mylan N.V. (United States), Gilead Sciences (United States) and Astellas (Japan)|
Breast cancer treatment market is a fragmented market due to the presence of various players. Companies are focusing on developing innovative products with different active drug combination and solutions to improve quality, enhances and promotes performance, along with try to incorporate latest advanced technology. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launch, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.
F. Hoffman - La Roche Ltd. (Switzerland), Celgene Corporation (United States), Bristol-Myers Squibb Company (United States), Abbot Laboratories Inc. (United States), Johnson & Johnson Services, Inc. (United States), Pfizer, Inc. (United States), AstraZeneca PLC (United Kingdom), Merck & Co. (United States), Novartis AG (Switzerland), AbbVie (United States), Mylan N.V. (United States), Gilead Sciences (United States) and Astellas (Japan) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
The study have segmented the market of Global Breast Cancer Treatment market by Type , by Application (Hospitals, Clinics, Pharmacy and Cancer Centers) and Region with country level break-up.
On the basis of geography, the market of Breast Cancer Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.
Market Leaders and their expansionary development strategiesIn October 2020, Gilead Sciences, Inc. acquired for roughly USD 21 billion in the aggregate. Under this acquisition Gilead promote Trodelvy at larger scale for patients with triple-negative breast cancer and its further use in other cancer treatment. This acquisition helped Gilead Sciences to expand its presence in breast cancer treatment market
In May 2022, Roche Pharma launched drug to treat breast cancer PHESGO. It contain two monoclonal antibodies - Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase and administer route is subcutaneous for early and metastatic breast cancer. This is first of Roche’s monoclonal antibody combination drug, which is useful to reduce treatment time by 90%. This launch helped company to expand its presence in breast cancer treatment
In October 2022, Roche received approval by US Food and Drug Administration (FDA) for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody which identify metastatic breast cancer patients with low HER2 expression for that Enhertu (fam-trastuzumab deruxtecan-nxki) considered as a targeted treatment. Enhertu is engineered HER2-directed antibody drug conjugate innovated and further manufactured under partnership of AstraZeneca and Daiichi Sankyo.
Influencing Trend:Increasing Demand for HR+/HER2+ Breast Cancer Treatments
Market Growth Drivers:Increasing Demand of Targeted Cancer Drug for Breast Cancer Treatment, Growing Demand for Breast Cancer Treatments Due To Rise in Breast Cancer Patients, Rising Awareness about Breast Cancer Treatment and Surge in Government’s Initiation in Awareness Programme for Breast Cancer Treatment
Challenges:Higher Incidence of Multidrug Resistance and Relapse. and Stringent Regulation for Innovation and Manufacturing of Breast Cancer Drug
Restraints:Presence of High Number of Side Effects Due To Breast Cancer Drug
Opportunities:Growing Investment in R&D of Breast Cancer Treatment and Increasing In Advance Innovation for Breast Cancer Treatments
Key Target AudienceBreast Cancer Treatment Provider, Breast Cancer drug manufacturer, Distributors, Government Bodies, Regulatory Bodies, Potential Investors, Research and Development Institutes, End Users and Others